Yazar "Arslan, Ahmet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Expression level of UCMA as a candidate molecular targetin osteoarthritis
    (2021) Okuyan, Hamza Malik; Arslan, Ahmet; Iğcı, Yusuf Ziya; Göğebakar, Bülent; Bilgiç, Nilüfer; Gündüz, Kübra; Sönmez, Dilara
    Aim: Osteoarthritis (OA) is a degenerative joint disorder that damages cartilage, synovium and subchondral bone, and there is yet no effective treatment for OA. The identification of novel therapeutic methods is crucially needed for better treatment of OA. Upper zone of growth plate and cartilage matrix associated (UCMA) was discovered as a chondrocyte specific protein in 2008, but its expression is solely not specific to cartilage tissue. Although UCMA is implicated in cartilage and bone metabolic processes, the molecular function of UCMA in OA is not elucidated yet. We aimed to examine the potential effect of UCMA in osteoblast metabolism associated with OA. Materials and Methods: We created an in vitro OA model by inducing osteoblast cell line with IL-1?. The expression levels of 12 related genes were determined using the qRT-PCR method. The MMP1 and OPG expression levels in the supernatants of cells were detected with ELISA. Results: We found that there was a dramatic increase in the levels of UCMA expression and other OA-related markers. We showed that IL-1? triggered the expression of main transcription factors playing a role during bone formation. MMP1 and OPG synthesis and secretions were increased in IL-1? induced-hFOB1.19 cell line significantly. Conclusion: Our study, as the first one using the human osteoblast cell line, provides good evidence about the potential value of UCMA in the pathophysiology of OA and shows that UCMA can be a promising molecular target to develop therapeutic approaches for OA.
  • Küçük Resim
    Öğe
    Expression of PARP1 gene in breast cancer patients
    (2013) Ulaşlı, Mustafa; Gürses, Serdar; Cengiz, Beyhan; Öztuzcu, Serdar; Balakan, Ozan; Süner, Ali; Göğebakan, Bülent; İğci, Mehri; Balık, Ahmet; Arslan, Ahmet; Camcı, Cemalettin
    Poli (ADP riboz) polimeraz (PARP), DNA onarım mekanizmasında yer alan bir enzim ailesidir. Bu enzimlerden PARP1, baz kesip- çıkarma onarım (BER) mekanizmasına öncülük eden tek zincir DNA kırıklarının saptanmasında rol alır. BRCA1 ve BRCA2 genlerinden yoksun meme kanseri tümörleri, DNA çift zincir kırıklarının onarımında yetersizdirler. PARP enzimlerinin bu tümörlerdeki aktivitesi ilgi konusudur çünkü PARP aktivitesinin kaybı, tek zincir DNA kırıklarının birikimine, biriken tek zincir DNA kırıklarının çift zincir DNA kırıklarına dönüşmesine ve takiben tamir edilemeyen DNA hasarı ve hücre ölümüne yol açmaktadır. Bu yüzden PARP inhibisyonunun, kanser hücrelerini öldürmede etkili olabileceği düşünülmekte ve PARP inhibitörlerinin seçici olarak meme kanseri tümörlerini öldürmedeki etkinliği araştırılmaktadır. Bu çalışmada, PARP inhibitörlerinin meme kanserine karşı kullanılma potansiyelinin değerlendirilmesi için bir grup meme kanserli hastada, PARP-1 gen ifade düzeyi ve kanser markırlarından östrojen reseptörü (ER), progesteron reseptörü (PR) ve insan epidermal büyüme faktör reseptörü 2 (HER2)’nin gen ifade düzeyleri belirlenmiştir. Hastalarda PARP-1 gen ifade düzeyinin meme kanseri oluşumu ile ilişkili olmadığı gösterilmiştir.
  • Küçük Resim
    Öğe
    Loss of heterozygosity of chromosome 13q33-34 region and molecular analysis of ING1 and p53 genes in bladder carcinoma
    (Springer, 2015) Igci, Mehri; Arslan, Ahmet; Erturhan, Sakip; Igci, Yusuf Ziya; Pala, Elif; Gogebakan, Bulent; Karakok, Metin
    Cancer is a consequence of accumulation of genetic and epigenetic alterations in the cell which can lead to activation of oncogenes or inactivation of tumor suppressor genes (TSG). Since members of ING family were discovered as TSGs in different cancer types, it was aimed to analyze the chromosome 13q33-34 region, ING1 and p53 genes in bladder cancer. 30 paired normal and tumor tissues were investigated in terms of microdeletion of chromosome 13q33-34 region, ING1 expression and mutation status of ING1 and p53 genes. Because there is no data available about the transcription factors which bind to ING1 promoter, the promoter sequence was analyzed via Genomatix-MatInspector and TFSEARCH softwares. Used DS markers were D13S285, D13S1315, D13S796, D13S278, D13S158, and D13S779 where loss of heterozygosity (LOH) results were as 23.3, 20, 6.7, 3.3, 6.7, and 0 %, respectively. The highest LOH scores were obtained with markers D13S285 and D13S1315 which are flanking the ING1. Seven of 30 cases showed alteration in expression (p > 0.05). However, no mutation was detected in the exons of ING1. One patient showed a two-nucleotide deletion in p53 gene. However no significant TSG activity of ING1 was observed while higher activity was reported in different cancer types. As for the LOH data 13q33-34 region may contain different candidate TSGs like COL4A1, COL4A2 and SOX1. As a result of computational promoter analysis, some factors like ABL, E2F, HIF1, SOX, P53, BPTF, NRSF, c-Rel and c-ETS were associated with the promoter region. Molecular analysis of ING1 promoter warrants further analysis.